Tomisaki Shinichi, Takenaka Tomoyoshi, Morizono Goki, Tanaka Tatsuya, Momosaki Nobuaki, Inoue Fumio
Dept. of Surgery, Arita Kyoritsu Hospital.
Gan To Kagaku Ryoho. 2009 Dec;36(13):2607-10.
A 69-year-old female, who had been admitted to another hospital with a complaint of headache and there detected brain tumor, was referred to our hospital for further examination and therapy. The patient was diagnosed as having advanced lung cancer with multiple brain metastasis. She was treated with five courses of a combination of chemotherapy consisting of carboplatin and paclitaxel following gamma knife radiotherapy. She showed a remarkable response, however, she experienced the side effects of general fatigue and numbness in her extremities, which were intolerable. Then, therapy with gefitinib alone was chosen as second-line chemotherapy. After one month, this therapy was discontinued due to grade 3 skin trouble and rash. When her condition improved, every other day oral administration of gefitinib was resumed. She has been treated on an outpatient basis because of no severe adverse reactions. The patient is alive with good performance status (PS) 0 more than one year after taking gefitinib. Furthermore, the primary and metastatic tumors are not enlarged. Gefitinib orally administered every other day could be a promising regimen as second-line chemotherapy for patients with lung cancer and brain metastasis.
一名69岁女性,因头痛入住另一家医院,在该院被查出患有脑肿瘤,后被转至我院进行进一步检查和治疗。该患者被诊断为晚期肺癌伴多发脑转移。在伽马刀放疗后,她接受了五个疗程的卡铂和紫杉醇联合化疗。她对此治疗反应显著,但出现了全身乏力和肢体麻木等难以耐受的副作用。随后,选择单独使用吉非替尼作为二线化疗。一个月后,因3级皮肤问题和皮疹,该治疗中断。当她的病情好转后,恢复每隔一天口服吉非替尼。由于没有严重不良反应,她一直作为门诊患者接受治疗。服用吉非替尼一年多后,患者存活,体能状态(PS)良好为0。此外,原发肿瘤和转移瘤均未增大。每隔一天口服吉非替尼可能是肺癌脑转移患者二线化疗的一种有前景的方案。